NTRK-fusions in pediatric thyroid tumors: Current state and future perspectives
•Somatic NTRK1 and NTRK3 fusions have high specificity for papillary thyroid cancer.•In pediatric PTC, NTRK fusions are associated with a high rate of regional and distant metastases.•Future studies needed to develop clinically relevant pediatric models of thyroid cancer. Pediatric and adult papilla...
Gespeichert in:
| Veröffentlicht in: | Cancer genetics 2022-06, Vol.264-265, p.23-28 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 28 |
|---|---|
| container_issue | |
| container_start_page | 23 |
| container_title | Cancer genetics |
| container_volume | 264-265 |
| creator | Casado-Medrano, Victoria O'Neill, Alison Halada, Stephen Laetsch, Theodore W. Bauer, Andrew J. Franco, Aime T. |
| description | •Somatic NTRK1 and NTRK3 fusions have high specificity for papillary thyroid cancer.•In pediatric PTC, NTRK fusions are associated with a high rate of regional and distant metastases.•Future studies needed to develop clinically relevant pediatric models of thyroid cancer.
Pediatric and adult papillary thyroid cancer (PTC) share many similar oncogenic drivers, but differ in the pathological features and outcomes of the disease. The most frequent genetic alterations in adult PTCs are mutually exclusive point mutations in BRAF or the RAS family. In pediatric PTC, fusion oncogenes involving chromosomal translocations in tyrosine kinase (TK) receptors, most commonly RET and NTRK, are the most common genetic alterations observed. This review of the literature describes the current state of translational research in pediatric NTRK-driven thyroid cancer and highlights opportunities to improve our understanding and current models of pediatric PTC. |
| doi_str_mv | 10.1016/j.cancergen.2022.02.009 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9133211</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S2210776222000151</els_id><sourcerecordid>2640047151</sourcerecordid><originalsourceid>FETCH-LOGICAL-c426t-f73a6bbfe3e1fd33b9aae56f10d0103351c4a9ccd7e0b8bed34e210202a8ebc23</originalsourceid><addsrcrecordid>eNqFUdtKAzEQDaLYUvsLuo--bM1lL10fhFK8YbEg9Tlkk9k2ZXdTk2yhf29Ka9Enw0AG5syZmXMQuiF4RDDJ7tYjKVoJdgntiGJKRzgELs5Qn1KC4zzP8fkpz2gPDZ1b4_CSFI9zdol6LKVFSIs-mr8vPt7iqnPatC7SbbQBpYW3WkZ-tbNGq8h3jbHuPpp21kLrI-eFh0i0Kqo631kILdZtQHq9BXeFLipROxge_wH6fHpcTF_i2fz5dTqZxTKhmY-rnImsLCtgQCrFWFkIAWlWEawwwYylRCaikFLlgMtxCYolEO4J14oxlJKyAXo48G66sgElw2JW1HxjdSPsjhuh-d9Kq1d8aba8IIxRQgLB7ZHAmq8OnOeNdhLqWrRgOsdplgTBcpLuofkBKq1xzkJ1GkMw3zvC1_zkCN87wnEIXITO699bnvp-9A-AyQEAQautBsud1BColLZBUa6M_nfINwY4o3I</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2640047151</pqid></control><display><type>article</type><title>NTRK-fusions in pediatric thyroid tumors: Current state and future perspectives</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Casado-Medrano, Victoria ; O'Neill, Alison ; Halada, Stephen ; Laetsch, Theodore W. ; Bauer, Andrew J. ; Franco, Aime T.</creator><creatorcontrib>Casado-Medrano, Victoria ; O'Neill, Alison ; Halada, Stephen ; Laetsch, Theodore W. ; Bauer, Andrew J. ; Franco, Aime T.</creatorcontrib><description>•Somatic NTRK1 and NTRK3 fusions have high specificity for papillary thyroid cancer.•In pediatric PTC, NTRK fusions are associated with a high rate of regional and distant metastases.•Future studies needed to develop clinically relevant pediatric models of thyroid cancer.
Pediatric and adult papillary thyroid cancer (PTC) share many similar oncogenic drivers, but differ in the pathological features and outcomes of the disease. The most frequent genetic alterations in adult PTCs are mutually exclusive point mutations in BRAF or the RAS family. In pediatric PTC, fusion oncogenes involving chromosomal translocations in tyrosine kinase (TK) receptors, most commonly RET and NTRK, are the most common genetic alterations observed. This review of the literature describes the current state of translational research in pediatric NTRK-driven thyroid cancer and highlights opportunities to improve our understanding and current models of pediatric PTC.</description><identifier>ISSN: 2210-7762</identifier><identifier>EISSN: 2210-7770</identifier><identifier>DOI: 10.1016/j.cancergen.2022.02.009</identifier><identifier>PMID: 35290879</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Adult thyroid cancer ; Child ; Gene Fusion ; Humans ; Mouse models ; Mutation - genetics ; NTRK fusion ; Oncogene ; Pediatric ; Proto-Oncogene Proteins B-raf - genetics ; Thyroid Cancer, Papillary - genetics ; Thyroid Neoplasms - genetics ; Thyroid Neoplasms - pathology</subject><ispartof>Cancer genetics, 2022-06, Vol.264-265, p.23-28</ispartof><rights>2022</rights><rights>Copyright © 2022. Published by Elsevier Inc.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c426t-f73a6bbfe3e1fd33b9aae56f10d0103351c4a9ccd7e0b8bed34e210202a8ebc23</citedby><cites>FETCH-LOGICAL-c426t-f73a6bbfe3e1fd33b9aae56f10d0103351c4a9ccd7e0b8bed34e210202a8ebc23</cites><orcidid>0000-0002-1677-5228 ; 0000-0002-3952-881X ; 0000-0002-6929-4559 ; 0000-0002-8497-3138</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S2210776222000151$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>230,314,776,780,881,3536,27903,27904,65309</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35290879$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Casado-Medrano, Victoria</creatorcontrib><creatorcontrib>O'Neill, Alison</creatorcontrib><creatorcontrib>Halada, Stephen</creatorcontrib><creatorcontrib>Laetsch, Theodore W.</creatorcontrib><creatorcontrib>Bauer, Andrew J.</creatorcontrib><creatorcontrib>Franco, Aime T.</creatorcontrib><title>NTRK-fusions in pediatric thyroid tumors: Current state and future perspectives</title><title>Cancer genetics</title><addtitle>Cancer Genet</addtitle><description>•Somatic NTRK1 and NTRK3 fusions have high specificity for papillary thyroid cancer.•In pediatric PTC, NTRK fusions are associated with a high rate of regional and distant metastases.•Future studies needed to develop clinically relevant pediatric models of thyroid cancer.
Pediatric and adult papillary thyroid cancer (PTC) share many similar oncogenic drivers, but differ in the pathological features and outcomes of the disease. The most frequent genetic alterations in adult PTCs are mutually exclusive point mutations in BRAF or the RAS family. In pediatric PTC, fusion oncogenes involving chromosomal translocations in tyrosine kinase (TK) receptors, most commonly RET and NTRK, are the most common genetic alterations observed. This review of the literature describes the current state of translational research in pediatric NTRK-driven thyroid cancer and highlights opportunities to improve our understanding and current models of pediatric PTC.</description><subject>Adult thyroid cancer</subject><subject>Child</subject><subject>Gene Fusion</subject><subject>Humans</subject><subject>Mouse models</subject><subject>Mutation - genetics</subject><subject>NTRK fusion</subject><subject>Oncogene</subject><subject>Pediatric</subject><subject>Proto-Oncogene Proteins B-raf - genetics</subject><subject>Thyroid Cancer, Papillary - genetics</subject><subject>Thyroid Neoplasms - genetics</subject><subject>Thyroid Neoplasms - pathology</subject><issn>2210-7762</issn><issn>2210-7770</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFUdtKAzEQDaLYUvsLuo--bM1lL10fhFK8YbEg9Tlkk9k2ZXdTk2yhf29Ka9Enw0AG5syZmXMQuiF4RDDJ7tYjKVoJdgntiGJKRzgELs5Qn1KC4zzP8fkpz2gPDZ1b4_CSFI9zdol6LKVFSIs-mr8vPt7iqnPatC7SbbQBpYW3WkZ-tbNGq8h3jbHuPpp21kLrI-eFh0i0Kqo631kILdZtQHq9BXeFLipROxge_wH6fHpcTF_i2fz5dTqZxTKhmY-rnImsLCtgQCrFWFkIAWlWEawwwYylRCaikFLlgMtxCYolEO4J14oxlJKyAXo48G66sgElw2JW1HxjdSPsjhuh-d9Kq1d8aba8IIxRQgLB7ZHAmq8OnOeNdhLqWrRgOsdplgTBcpLuofkBKq1xzkJ1GkMw3zvC1_zkCN87wnEIXITO699bnvp-9A-AyQEAQautBsud1BColLZBUa6M_nfINwY4o3I</recordid><startdate>20220601</startdate><enddate>20220601</enddate><creator>Casado-Medrano, Victoria</creator><creator>O'Neill, Alison</creator><creator>Halada, Stephen</creator><creator>Laetsch, Theodore W.</creator><creator>Bauer, Andrew J.</creator><creator>Franco, Aime T.</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-1677-5228</orcidid><orcidid>https://orcid.org/0000-0002-3952-881X</orcidid><orcidid>https://orcid.org/0000-0002-6929-4559</orcidid><orcidid>https://orcid.org/0000-0002-8497-3138</orcidid></search><sort><creationdate>20220601</creationdate><title>NTRK-fusions in pediatric thyroid tumors: Current state and future perspectives</title><author>Casado-Medrano, Victoria ; O'Neill, Alison ; Halada, Stephen ; Laetsch, Theodore W. ; Bauer, Andrew J. ; Franco, Aime T.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c426t-f73a6bbfe3e1fd33b9aae56f10d0103351c4a9ccd7e0b8bed34e210202a8ebc23</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Adult thyroid cancer</topic><topic>Child</topic><topic>Gene Fusion</topic><topic>Humans</topic><topic>Mouse models</topic><topic>Mutation - genetics</topic><topic>NTRK fusion</topic><topic>Oncogene</topic><topic>Pediatric</topic><topic>Proto-Oncogene Proteins B-raf - genetics</topic><topic>Thyroid Cancer, Papillary - genetics</topic><topic>Thyroid Neoplasms - genetics</topic><topic>Thyroid Neoplasms - pathology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Casado-Medrano, Victoria</creatorcontrib><creatorcontrib>O'Neill, Alison</creatorcontrib><creatorcontrib>Halada, Stephen</creatorcontrib><creatorcontrib>Laetsch, Theodore W.</creatorcontrib><creatorcontrib>Bauer, Andrew J.</creatorcontrib><creatorcontrib>Franco, Aime T.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Cancer genetics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Casado-Medrano, Victoria</au><au>O'Neill, Alison</au><au>Halada, Stephen</au><au>Laetsch, Theodore W.</au><au>Bauer, Andrew J.</au><au>Franco, Aime T.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>NTRK-fusions in pediatric thyroid tumors: Current state and future perspectives</atitle><jtitle>Cancer genetics</jtitle><addtitle>Cancer Genet</addtitle><date>2022-06-01</date><risdate>2022</risdate><volume>264-265</volume><spage>23</spage><epage>28</epage><pages>23-28</pages><issn>2210-7762</issn><eissn>2210-7770</eissn><abstract>•Somatic NTRK1 and NTRK3 fusions have high specificity for papillary thyroid cancer.•In pediatric PTC, NTRK fusions are associated with a high rate of regional and distant metastases.•Future studies needed to develop clinically relevant pediatric models of thyroid cancer.
Pediatric and adult papillary thyroid cancer (PTC) share many similar oncogenic drivers, but differ in the pathological features and outcomes of the disease. The most frequent genetic alterations in adult PTCs are mutually exclusive point mutations in BRAF or the RAS family. In pediatric PTC, fusion oncogenes involving chromosomal translocations in tyrosine kinase (TK) receptors, most commonly RET and NTRK, are the most common genetic alterations observed. This review of the literature describes the current state of translational research in pediatric NTRK-driven thyroid cancer and highlights opportunities to improve our understanding and current models of pediatric PTC.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>35290879</pmid><doi>10.1016/j.cancergen.2022.02.009</doi><tpages>6</tpages><orcidid>https://orcid.org/0000-0002-1677-5228</orcidid><orcidid>https://orcid.org/0000-0002-3952-881X</orcidid><orcidid>https://orcid.org/0000-0002-6929-4559</orcidid><orcidid>https://orcid.org/0000-0002-8497-3138</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2210-7762 |
| ispartof | Cancer genetics, 2022-06, Vol.264-265, p.23-28 |
| issn | 2210-7762 2210-7770 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9133211 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Adult thyroid cancer Child Gene Fusion Humans Mouse models Mutation - genetics NTRK fusion Oncogene Pediatric Proto-Oncogene Proteins B-raf - genetics Thyroid Cancer, Papillary - genetics Thyroid Neoplasms - genetics Thyroid Neoplasms - pathology |
| title | NTRK-fusions in pediatric thyroid tumors: Current state and future perspectives |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-23T21%3A24%3A52IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=NTRK-fusions%20in%20pediatric%20thyroid%20tumors:%20Current%20state%20and%20future%20perspectives&rft.jtitle=Cancer%20genetics&rft.au=Casado-Medrano,%20Victoria&rft.date=2022-06-01&rft.volume=264-265&rft.spage=23&rft.epage=28&rft.pages=23-28&rft.issn=2210-7762&rft.eissn=2210-7770&rft_id=info:doi/10.1016/j.cancergen.2022.02.009&rft_dat=%3Cproquest_pubme%3E2640047151%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2640047151&rft_id=info:pmid/35290879&rft_els_id=S2210776222000151&rfr_iscdi=true |